Regulatory Approvals, Product Launches, and Steady Sales Show Signs of Growth - Research Report on Johnson & Johnson, Bristol-Myers Squibb, Actavis, Edwards Lifesciences, and Health Net

NEW YORK, July 30, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb Company (NYSE: BMY), Actavis Inc. (NYSE: ACT), Edwards Lifesciences Corp. (NYSE: EW), and Health Net, Inc. (NYSE: HNT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On July 18, 2013, Janssen Biotech, Inc., a Johnson & Johnson (Johnson & Johnson) company, announced that the US Food and Drug Administration (FDA) has approved SIMPONI ARIA (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate. According to Janssen, SIMPONI ARIA, the only fully-human anti-tumor necrosis factor (TNF)-alpha infusible therapy, has been shown to significantly improve signs and symptoms of physical function, and inhibit the progression of structural damage. Sergio Schwartzman, M.D., Director, Inflammatory Arthritis Center, Hospital for Special Surgery, Associate Professor, Weill Cornell Medical College, and Advisory Board Member, said, "The approval of SIMPONI ARIA offers rheumatologists a new anti-TNF infusible treatment for patients who demonstrate an inadequate response to methotrexate; having treatment options remains critical for us to continue to meet the needs of our patients." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

--

Bristol-Myers Squibb Company Research Report

On July 25, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) reported its financial results for Q2 2013. Net sales decreased 8.9% YoY to $4.0 billion. Net earnings attributable to Bristol-Myers Squibb were $536 million or $0.32 per diluted share in Q2 2013 compared to $645 or $0.38 per diluted share in Q2 2012. Lamberto Andreotti, Chief Executive Officer of Bristol-Myers Squibb, said, "In the second quarter, the strength in the performance of some of our key products, the important data we presented across our portfolio and the key regulatory filings we made in the U.S. strengthen our confidence as we build a solid foundation for future growth." The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/81a9_BMY]

--

Actavis Inc. Research Report

On July 25, 2013, Actavis Inc. (Actavis) reported its financial results for Q2 2013. Net revenue increased 46.8% YoY to approximately $2 billion. On a GAAP basis, the Company reported net loss of $564.6 million or $4.27 per diluted share in Q2 2013 compared to net loss of $62.2 million or $0.49 per diluted share in Q2 2012. GAAP results included an impairment charge pertaining to a routine annual impairment testing. Paul Bisaro, President and Chief Executive Officer of Actavis, said, "Actavis delivered another exceptional quarter of double-digit sales and earnings growth powered by strong generics launches in global markets by Actavis Pharma, continued strong sales of core specialty Brand products and consistent execution by our Global Operations team." The Full Research Report on Actavis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4997_ACT]

--

Edwards Lifesciences Corp. Research Report

On July 25, 2013, Edwards Lifesciences Corp. (Edwards Lifesciences) reported its financial results for Q2 2013. Net sales increased 7.3% YoY to $517.2 million. Net income was $94.1 million or $0.82 per diluted share, compared to net income of $67.8 million or $0.57 per diluted share in Q2 2012. Michael A. Mussallem, Chairman and Chief Executive Officer of Edwards Lifesciences, said, "We are pleased to report solid second quarter results, driven by strong sales of transcatheter and surgical heart valves in both the U.S. and Europe. Our SAPIEN launch in the U.S. continues to be highlighted by very high procedural success rates and we are gratified to see this therapy changing the lives of so many patients." The Full Research Report on Edwards Lifesciences Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/48b8_EW]

--

Health Net, Inc. Research Report

On July 25, 2013, Health Net Inc. (Health Net) reported its financial results for Q2 2013. Total revenues decreased 3.6% YoY to $2.7 billion. Net income was $33.5 million or $0.42 per diluted share in Q2 2013 compared to net income of $124.6 million or $1.48 per diluted share in Q2 2012. Q2 2013 GAAP results include approximately $12.9 million in Corporate/Other pretax expenses, primarily severance costs resulting from the Company's continuing efforts to address scale issues. Q2 2012 results also include a $119.4 million net gain or $1.42 per diluted share from the sale of the Company's Medicare PDP business. The Full Research Report on Health Net, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/6995_HNT]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://AnalystsCorner.com

 

SOURCE Analysts' Corner

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.